Analyst Reco. Affimed N.V.

Equities

AFMD

NL0015001ZQ0

Real-time Estimate Cboe BZX Other stock markets 02:27:07 2024-04-29 pm EDT			5-day change	1st Jan Change
5.45 ^USD	+8.35%		+7.10%	-14.32%

Apr. 01	Wells Fargo Cuts Affimed Price Target to $25 From $30, Maintains Overweight Rating	MT
Apr. 01	HC Wainwright Adjusts Affimed's Price Target to $10 From $50, Maintains Buy Rating	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Wells Fargo Cuts Affimed Price Target to $25 From $30, Maintains Overweight Rating	Apr. 01	MT
HC Wainwright Adjusts Affimed's Price Target to $10 From $50, Maintains Buy Rating	Apr. 01	MT
Truist Securities Adjusts Price Target on Affimed to $6 From $8, Keeps Buy Rating	23-08-11	MT
Berenberg Assumes Affimed at Buy, Sets Price Target at $6	23-08-08	MT
HC Wainwright Trims Price Target on Affimed to $5 From $6, Maintains Buy Rating	23-06-05	MT
Berenberg Bank Adjusts Affimed Price Target to $6 From $10, Maintains Buy Rating	23-05-24	MT
Stifel Adjusts Price Target on Affimed to $1 From $2, Maintains Hold Rating	23-03-24	MT
Wells Fargo Adjusts Price Target on Affimed to $7 From $8, Maintains Overweight Rating	22-12-12	MT
Wall Street Set to Open Higher as Investors Await Inflation Data, Fed Rate Decision in Coming Days	22-12-12	MT
US Futures Move Modestly Higher Monday Ahead of Inflation Data Tuesday, Fed Rate Decision Meeting Conclusion Wednesday	22-12-12	MT
SVB Securities Adjusts Affimed's Price Target to $6 From $10, Keeps Outperform Rating	22-12-12	MT
Piper Sandler Adjusts Affimed's Price Target to $6 From $7, Keeps Overweight Rating	22-12-12	MT
HC Wainwright Starts Affimed at Buy With $6 Price Target	22-12-12	MT
Stifel Downgrades Affimed to Hold From Buy, Adjusts Price Target to $2 From $9	22-10-10	MT
Berenberg Bank Adjusts Affimed's Price Target to $10 From $11, Maintains Buy Rating	22-08-12	MT
SVB Securities Adjusts Affimed Price Target to $9 From $10, Maintains Outperform Rating	22-06-23	MT
Affimed N.V.'s Potential Therapy for Lymphoma Shows 100% Objective Response Rate in Phase 1/2 Study	22-04-11	MT
Piper Sandler Starts Affimed at Overweight With $7 Price Target	22-03-31	MT
Cantor Fitzgerald Initiates Affimed at Overweight with $12 Price Target	22-02-23	MT
Affimed NV's Innate Cell Engager Achieves 100% Objective Response Rate In Phase 1/2 Lymphoma Study	21-11-22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Affimed N.V.

Equities

AFMD

NL0015001ZQ0

Analyst Reco.

Filters